Drew litigates complex intellectual property cases and high-stakes commercial disputes. Drew graduated first in his class and was Editor-in-Chief of the law review at the University of Connecticut School of Law, which he attended on a full-tuition merit scholarship. He is a Phi Beta Kappa graduate of Saint Louis University, where he earned his BA, summa cum laude.
Drew joined Axinn as a summer associate. He returned to Axinn's Intellectual Property group as an associate in 2016, following a clerkship with Judge Michael P. Shea of the United States District Court for the District of Connecticut. He served previously as a judicial intern to Judge Janet Bond Arterton of the United States District Court for the District of Connecticut.
Drew is an active member of an alumni leadership committee for Saint Louis University. In his pro bono practice, Drew tries civil rights cases by judicial appointment in federal district court.
- Law Clerk to the Honorable Michael P. Shea of the United States District Court for the District of Connecticut (2015 – 2016)
- Litigated in federal district court on behalf of pharmaceutical company involving roughly three dozen patents from seven patent families directed to controlled release or abuse deterrent dosage forms.
- Counseled makers of biologic medical products about litigation and development strategies.
- Represented innovator-company and manufacturer of spinal implants in state and federal lawsuits over patent royalties and disputed inventorship.
- After being appointed by a federal district court to represent a pro bono client in a civil rights suit, obtained a settlement with an economic value of more than $1 million.
- Counseled tissue-provider about licensing of osteochondral-graft technology.
- Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge, The Center for Biosimilars, November 11, 2020
- Federal Circuit to Decide Limits on Functional Claiming of Isolated Monoclonal Antibodies, Biosimilar Development, October 22, 2020
- Open Source Patent Licenses: Pitfalls and Opportunity, Bloomberg Law, June 5, 2020
- FDA’s Emergency Use Authorizations: Aggressive Action Taken to Combat COVID-19, Contract Pharma, April 20, 2020
- FDA Emergency Use Authorizations, Lexis Practice Advisor Journal, April 1, 2020
- Little Impact Post-Arthrex for Biologic Patents at the PTAB, The Center for Biosimilars, December 3, 2019
- How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy, Biosimilar Development, July 23, 2019
- Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law, BioProcess International, May 17, 2019
- 2018 Year-End Roundup of Federal Circuit Obviousness Decisions in Biopharma, Westlaw Journal Pharmaceutical, April 9, 2019
- A Hard Choice for Abbreviated Biologics License Applicants, Law360, February 4, 2019
- 2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways, Westlaw Journal, April 17, 2018
- The Necessity of an Equity and Comity Analysis in Younger Abstention Doctrine, Connecticut Law Review, July 2014
- JD, highest honors – University of Connecticut School of Law (2015)
- BA, summa cum laude – Saint Louis University (2010), Phi Beta Kappa
- Diplôme Universitaire de Langue et de Culture Françaises – Université Catholique de Lyon (2009)
- US Court of Appeals for the Federal Circuit
- US Court of Appeals for the Second Circuit
- US Court of Appeals for the Ninth Circuit
- US District Court, District of Connecticut
- US District Court, Southern District of New York
- US District Court, Eastern District of New York